Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business

This article was originally published in The Pink Sheet Daily

Executive Summary

Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.

You may also be interested in...



When Will Pfizer Be Ready For Its Next Big (Or Small) Move?

A year after its failed takeover bid for AstraZeneca, Pfizer Inc. continues to face questions about whether it will pursue another large-scale merger, and how it is preparing for a potential spin off.

What Does Pfizer’s Read Have To Say About It? A Lot, Actually

Pfizer CEO Ian Read voiced his opinions on some of industry’s hottest topics – everything from the pricing of Sovaldi to M&A to the latest innovations, like gene therapy – during a far-ranging discussion at the BIO CEO & Investor conference Feb. 10.

Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)

Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel